Mario Cazzola

Qualifica
ASSOCIATO CONFERMATO
Fonte dei dati: Archivio della Ricerca http://art.torvergata.it
  1. Calzetta, L., Ludovica Ritondo, B., de Marco, P., Cazzola, M., & Rogliani, P. (2021). Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. EXPERT REVIEW OF RESPIRATORY MEDICINE, 15(4), 579-581 [10.1080/17476348.2021.1866835]. Dettagli
  2. Cazzola, M., Ora, J., Bianco, A., Rogliani, P., & Matera, M.G. (2021). Guidance on nebulization during the current COVID-19 pandemic. RESPIRATORY MEDICINE, 176, 106236 [10.1016/j.rmed.2020.106236]. Dettagli
  3. Rogliani, P., Ritondo, B.L., Ora, J., Cazzola, M., & Calzetta, L. (2020). SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. EUROPEAN RESPIRATORY JOURNAL, 56(3), 2000625 [10.1183/13993003.00625-2020]. Dettagli
  4. Calzetta, L., Matera, M.G., Rogliani, P., & Cazzola, M. (2020). The role of triple therapy in the management of COPD. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 13(8), 865-874 [10.1080/17512433.2020.1787830]. Dettagli
  5. Cazzola, M., Stolz, D., Rogliani, P., & Matera, M.G. (2020). α1-Antitrypsin deficiency and chronic respiratory disorders. EUROPEAN RESPIRATORY REVIEW, 29(155), 190073. Dettagli
  6. Bernard, E., Nannya, Y., Hasserjian, R.P., Devlin, S.M., Tuechler, H., Medina-Martinez, J.S., et al. (2020). Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. NATURE MEDICINE, 26(10), 1549-1556. Dettagli
  7. Calzetta, L., Matera, M.G., Goldstein, M.F., Fairweather, W.R., Howard, W.W., Cazzola, M., et al. (2020). A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. PULMONARY PHARMACOLOGY & THERAPEUTICS, 60, 101883. Dettagli
  8. Cazzola, M., Rogliani, P., Calzetta, L., & Matera, M.G. (2020). Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy. PHARMACOGENOMICS AND PERSONALIZED MEDICINE, 13, 261-271 [10.2147/PGPM.S231471]. Dettagli
  9. Matera, M.G., Page, C.P., Calzetta, L., Rogliani, P., & Cazzola, M. (2020). Pharmacology and Therapeutics of Bronchodilators Revisited. PHARMACOLOGICAL REVIEWS, 72(1), 218-252 [10.1124/pr.119.018150]. Dettagli
  10. Matera, M.G., Rogliani, P., Bianco, A., & Cazzola, M. (2020). Pharmacological management of adult patients with acute respiratory distress syndrome. EXPERT OPINION ON PHARMACOTHERAPY, 21(17), 2169-2183 [10.1080/14656566.2020.1801636]. Dettagli
  11. Rogliani, P., Matera, M.G., Facciolo, F., Page, C., Cazzola, M., & Calzetta, L. (2020). Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. BRITISH JOURNAL OF PHARMACOLOGY, 177(5), 1150-1163 [10.1111/bph.14909]. Dettagli
  12. Rogliani, P., Ritondo, B.L., Zerillo, B., Cazzola, M., Matera, M.G., & Calzetta, L. (2020). Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. COPD, 17(2), 215-223. Dettagli
  13. Cazzola, M., Rogliani, P., & Matera, M.G. (2019). The future of bronchodilation: looking for new classes of bronchodilators. EUROPEAN RESPIRATORY REVIEW, 28(154), 190095. Dettagli
  14. Calzetta, L., Cazzola, M., Matera, M.G., & Rogliani, P. (2019). Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. CHEST, 155(4), 758-770 [10.1016/j.chest.2018.12.016]. Dettagli
  15. Calzetta, L., Cazzola, M., Matera, M.g., & Rogliani, P. (2019). Response. CHEST, 155(5), 1079-1080 [10.1016/j.chest.2019.01.028]. Dettagli
  16. Calzetta, L., Di Marco, F., Blasi, F., Cazzola, M., Centanni, S., Micheletto, C., et al. (2019). Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 59, 101855 [10.1016/j.pupt.2019.101855]. Dettagli
  17. Calzetta, L., Gabriella Matera, M., Rogliani, P., & Cazzola, M. (2019). Dual phosphodiesterase PDE3/4 inhibitor Treatment of COPD Treatment of cystic fibrosis. DRUGS OF THE FUTURE, 44(11), 845-854. Dettagli
  18. Calzetta, L., Matera, M.G., Cazzola, M., & Rogliani, P. (2019). Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. ADVANCES IN THERAPY, 36(12), 3291-3298. Dettagli
  19. Calzetta, L., Rogliani, P., Page, C., Rinaldi, B., Cazzola, M., & Matera, M.g. (2019). Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. PULMONARY PHARMACOLOGY & THERAPEUTICS, 56, 39-50 [10.1016/j.pupt.2019.03.004]. Dettagli
  20. Cazzola, M., Calzetta, L., Page, C., Rogliani, P., & Matera, M.g. (2019). Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. TRENDS IN PHARMACOLOGICAL SCIENCES, 40(7), 452-463 [10.1016/j.tips.2019.04.015]. Dettagli
  21. Cazzola, M., Calzetta, L., Rogliani, P., & Matera, M.g. (2019). Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 28(10), 827-833 [10.1080/13543784.2019.1661990]. Dettagli
  22. Cazzola, M., Puxeddu, E., Matera, M.g., & Rogliani, P. (2019). A potential role of triple therapy for asthma patients. EXPERT REVIEW OF RESPIRATORY MEDICINE, 13(11), 1079-1085 [10.1080/17476348.2019.1657408]. Dettagli
  23. Cazzola, M., Rogliani, P., & Matera, M.g. (2019). Ultra-LABAs for the treatment of asthma. RESPIRATORY MEDICINE, 156, 47-52 [10.1016/j.rmed.2019.08.005]. Dettagli
  24. Cazzola, M., Rogliani, P., Calzetta, L., & Matera, M.g. (2019). Bronchodilators in subjects with asthma-related comorbidities. RESPIRATORY MEDICINE, 151, 43-48 [10.1016/j.rmed.2019.04.001]. Dettagli
  25. Cazzola, M., Rogliani, P., Stolz, D., & Matera, M.G. (2019). Pharmacological treatment and current controversies in COPD. F1000RESEARCH, 8, 1533. Dettagli
  26. Matera, M.g., Calzetta, L., Rogliani, P., & Cazzola, M. (2019). Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. RESPIRATORY MEDICINE, 153, 3-13 [10.1016/j.rmed.2019.05.005]. Dettagli
  27. Matera, M.g., Rinaldi, B., Calzetta, L., Rogliani, P., & Cazzola, M. (2019). Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. PULMONARY PHARMACOLOGY & THERAPEUTICS, 58, 101828 [10.1016/j.pupt.2019.101828]. Dettagli
  28. Rogliani, P., Calzetta, L., Matera, M.g., di Daniele, N., Girolami, A., Cazzola, M., et al. (2019). Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 20(6), 737-750 [10.1080/14656566.2019.1570133]. Dettagli
  29. Rogliani, P., Calzetta, L., Ora, J., Cazzola, M., & Matera, M.g. (2019). Efficacy and safety profile of doxofylline compared to theophylline in asthma: A meta-analysis. MULTIDISCIPLINARY RESPIRATORY MEDICINE, 14(1) [10.1186/s40248-019-0189-0]. Dettagli
  30. Rogliani, P., Cazzola, M., & Calzetta, L. (2019). Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 73(17), 2178-2180 [10.1016/j.jacc.2018.11.068]. Dettagli
  31. Rogliani, P., Matera, M.G., Page, C., Puxeddu, E., Cazzola, M., & Calzetta, L. (2019). Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. RESPIRATORY RESEARCH, 20(1) [10.1186/s12931-019-1078-y]. Dettagli
  32. Rogliani, P., Matera, M.g., Calzetta, L., Hanania, N.a., Page, C., Rossi, I., et al. (2019). Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. RESPIRATORY MEDICINE, 154, 86-92 [10.1016/j.rmed.2019.06.015]. Dettagli
  33. Rogliani, P., Matera, M.g., Ritondo, B.l., De Guido, I., Puxeddu, E., Cazzola, M., et al. (2019). Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. PULMONARY PHARMACOLOGY & THERAPEUTICS, 59, 101841 [10.1016/j.pupt.2019.101841]. Dettagli
  34. Sposato, B., Scalese, M., Milanese, M., Masieri, S., Cavaliere, C., Latorre, M., et al. (2019). Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE, 7(5), 1643-1646 [10.1016/j.jaip.2019.03.006]. Dettagli
  35. Cazzola, M., Matera, M.g., Levi-Schaffer, F., & Rogliani, P. (2018). Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. EXPERT OPINION ON DRUG SAFETY [10.1080/14740338.2018.1446940]. Dettagli
  36. Cazzola, M., Rogliani, P., & Matera, M.g. (2018). Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 128(1), 895-897-897 [10.20452/pamw.4197]. Dettagli
  37. Calzetta, L., Matera, M.G., Facciolo, F., Cazzola, M., & Rogliani, P. (2018). Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. RESPIRATORY RESEARCH, 19(1), 65 [10.1186/s12931-018-0770-7]. Dettagli
  38. Calzetta, L., Matera, M.g., Rogliani, P., & Cazzola, M. (2018). Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. EXPERT REVIEW OF RESPIRATORY MEDICINE, 12(4), 261-264 [10.1080/17476348.2018.1442216]. Dettagli
  39. Calzetta, L., Matera, M.g., Rogliani, P., & Cazzola, M. (2018). Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. EXPERT REVIEW OF RESPIRATORY MEDICINE, 12(8), 693-708 [10.1080/17476348.2018.1495562]. Dettagli
  40. Calzetta, L., Rogliani, P., Facciolo, F., Rinaldi, B., Cazzola, M., & Matera, M.g. (2018). N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. BIOMÉDECINE & PHARMACOTHÉRAPIE, 103, 1-8 [10.1016/j.biopha.2018.04.011]. Dettagli
  41. Cazzola, M., & Rogliani, P. (2018). Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. BMJ EVIDENCE-BASED MEDICINE, 23(5), 183-184 [10.1136/bmjebm-2018-110940]. Dettagli
  42. Cazzola, M., Calzetta, L., Matera, M.g., Hanania, N.a., & Rogliani, P. (2018). How does race/ethnicity influence pharmacological response to asthma therapies?. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(4), 435-446 [10.1080/17425255.2018.1449833]. Dettagli
  43. Cazzola, M., Calzetta, L., Page, C., Rogliani, P., & Matera, M.g. (2018). Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 48, 185-194 [10.1016/j.pupt.2017.11.009]. Dettagli
  44. Cazzola, M., Calzetta, L., Rogliani, P., Page, C., & Matera, M.g. (2018). Impact of doxofylline in COPD: A pairwise meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 51, 1-9 [10.1016/j.pupt.2018.04.010]. Dettagli
  45. Cazzola, M., Matera, M.g., Rogliani, P., & Calzetta, L. (2018). Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 27(7), 573-581 [10.1080/13543784.2018.1492548]. Dettagli
  46. Cazzola, M., Rogliani, P., Calzetta, L., & Matera, M.G. (2018). Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. EUROPEAN RESPIRATORY JOURNAL, 52(6). Dettagli
  47. Cazzola, M., Rogliani, P., Puxeddu, E., Ora, J., & Matera, M.g. (2018). An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. EXPERT REVIEW OF RESPIRATORY MEDICINE, 12(1), 43-54 [10.1080/17476348.2018.1398086]. Dettagli
  48. Mantero, M., Rogliani, P., Cazzola, M., Blasi, F., & Di Pasquale, M. (2018). Emerging antibacterial and antiviral drugs for treating respiratory tract infections. EXPERT OPINION ON EMERGING DRUGS, 23(3), 185-199 [10.1080/14728214.2018.1504020]. Dettagli
  49. Matera, M.g., Calzetta, L., Gritti, G., Gallo, L., Perfetto, B., Donnarumma, G., et al. (2018). Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. EUROPEAN JOURNAL OF PHARMACOLOGY, 832, 114-119 [10.1016/j.ejphar.2018.05.023]. Dettagli
  50. Matera, M.g., Rinaldi, B., Page, C., Rogliani, P., & Cazzola, M. (2018). Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(10), 1101-1111 [10.1080/17425255.2018.1530215]. Dettagli
  51. Matera, M.g., Rogliani, P., Calzetta, L., & Cazzola, M. (2018). Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(2), 239-245 [10.1080/17425255.2018.1421170]. Dettagli
  52. Matera, M.g., Rogliani, P., Ora, J., & Cazzola, M. (2018). Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. EXPERT OPINION ON PHARMACOTHERAPY, 19(18), 2043-2053 [10.1080/14656566.2018.1534957]. Dettagli
  53. Rogliani, P., Calzetta, L., & Cazzola, M. (2018). Is ICS–LAMA an alternative option to treat patients with COPD?. THE LANCET RESPIRATORY MEDICINE [10.1016/S2213-2600(18)30139-5]. Dettagli
  54. Rogliani, P., Calzetta, L., Braido, F., Cazzola, M., Clini, E., Pelaia, G., et al. (2018). LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. INTERNATIONAL JOURNAL OF COPD, 13, 3115-3130 [10.2147/COPD.S170606]. Dettagli
  55. Rogliani, P., Matera, M.g., Puxeddu, E., Mantero, M., Blasi, F., Cazzola, M., et al. (2018). Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 50, 28-37 [10.1016/j.pupt.2018.03.004]. Dettagli
  56. Rogliani, P., Ora, J., Matera, M.g., Cazzola, M., & Calzetta, L. (2018). The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. EXPERT OPINION ON DRUG SAFETY, 17(6), 589-596 [10.1080/14740338.2018.1472232]. Dettagli
  57. Rogliani, P., Ora, J., Puxeddu, E., Calzetta, L., Cavalli, F., Matera, M.g., et al. (2018). Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. PULMONARY PHARMACOLOGY & THERAPEUTICS, 49, 20-26 [10.1016/j.pupt.2017.12.010]. Dettagli
  58. Cazzola, M., Rogliani, P., Aliberti, S., Blasi, F., & Matera, M. (2017). An update on the pharmacotherapeutic management of lower respiratory tract infections. EXPERT OPINION ON PHARMACOTHERAPY, 18(10), 973-988 [10.1080/14656566.2017.1328497]. Dettagli
  59. CALZETTA, L., Matera, M., Braido, F., Contoli, M., Corsico, A., Di Marco, F., et al. (2017). Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 45, 148-158 [10.1016/j.pupt.2017.06.002]. Dettagli
  60. Calzetta, L., Ora, J., Cavalli, F., Rogliani, P., O'Donnell, D.e., & Cazzola, M. (2017). Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. RESPIRATORY MEDICINE, 129, 189-198 [10.1016/j.rmed.2017.06.020]. Dettagli
  61. Calzetta, L., Rogliani, P., Facciolo, F., Rendina, E., Cazzola, M., & Matera, M.g. (2017). Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. EUROPEAN JOURNAL OF PHARMACOLOGY [10.1016/j.ejphar.2017.07.026]. Dettagli
  62. Calzetta, L., Rogliani, P., Mattei, M., Alfonsi, P., Cito, G., Pistocchini, E., et al. (2017). Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD, 14(5), 526-532 [10.1080/15412555.2017.1344627]. Dettagli
  63. Calzetta, L., Rogliani, P., Ora, J., Puxeddu, E., Cazzola, M., & Matera, M.g. (2017). LABA/LAMA combination in copd: A meta-analysis on the duration of treatment. EUROPEAN RESPIRATORY REVIEW, 26(143), 160043 [10.1183/16000617.0043-2016]. Dettagli
  64. Cazzola, M., & Rogliani, P. (2017). Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 6(7), 627-636 [10.2217/cer-2017-0037]. Dettagli
  65. Cazzola, M., & Rogliani, P. (2017). In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids. EVIDENCE-BASED MEDICINE, 22(5), 183-184 [10.1136/ebmed-2017-110726]. Dettagli
  66. Cazzola, M., Calzetta, L., Facciolo, F., Rogliani, P., & Matera, M. (2017). Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. RESPIRATORY RESEARCH, 18(1). Dettagli
  67. Cazzola, M., Calzetta, L., Rinaldi, B., Page, C., Rosano, G., Rogliani, P., et al. (2017). Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. DRUGS, 77(7), 721-732 [10.1007/s40265-017-0731-3]. Dettagli
  68. Cazzola, M., Calzetta, L., Rogliani, P., & Matera, M. (2017). The Challenges of Precision Medicine in COPD. MOLECULAR DIAGNOSIS & THERAPY, 21(4), 345-355 [10.1007/s40291-017-0266-z]. Dettagli
  69. Cazzola, M., Calzetta, L., Rogliani, P., & Matera, M.g. (2017). Tiotropium formulations and safety: a network meta-analysis. THERAPEUTIC ADVANCES IN DRUG SAFETY, 8(1), 17-30 [10.1177/2042098616667304]. Dettagli
  70. Cazzola, M., Ora, J., Rogliani, P., & Matera, M.g. (2017). Role of muscarinic antagonists in asthma therapy. EXPERT REVIEW OF RESPIRATORY MEDICINE, 11(3), 239-253 [10.1080/17476348.2017.1289844]. Dettagli
  71. Cazzola, M., Rogliani, P., Calzetta, L., Hanania, N.a., & Matera, M.g. (2017). Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD, 14(5), 552-563 [10.1080/15412555.2017.1347918]. Dettagli
  72. Cazzola, M., Rogliani, P., Calzetta, L., Lauro, D., Page, C., & Matera, M.g. (2017). Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. TRENDS IN PHARMACOLOGICAL SCIENCES, 38(10), 940-951 [10.1016/j.tips.2017.07.003]. Dettagli
  73. Mantero, M., Rogliani, P., Di Pasquale, M., Polverino, E., Crisafulli, E., Guerrero, M., et al. (2017). Acute exacerbations of COPD: Risk factors for failure and relapse. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 2687-2693 [10.2147/COPD.S145253]. Dettagli
  74. Matera, M.g., Rogliani, P., Zanasi, A., & Cazzola, M. (2017). Bronchodilator therapy for chronic cough. PULMONARY PHARMACOLOGY & THERAPEUTICS [10.1016/j.pupt.2017.05.011]. Dettagli
  75. ROGLIANI, P., CALZETTA, L., Coppola, A., Cavalli, F., Ora, J., PUXEDDU, E., et al. (2017). Optimizing drug delivery in COPD: The role of inhaler devices. RESPIRATORY MEDICINE, 124, 6-14 [10.1016/j.rmed.2017.01.006]. Dettagli
  76. Rogliani, P., Matera, M.g., Ora, J., Cazzola, M., & Calzetta, L. (2017). The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: A quantitative synthesis. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 3469-3485 [10.2147/COPD.S146338]. Dettagli
  77. Rogliani, P., Ora, J., Puxeddu, E., Matera, M.g., & Cazzola, M. (2017). Adherence to COPD treatment: Myth and reality. RESPIRATORY MEDICINE, 129, 117-123 [10.1016/j.rmed.2017.06.007]. Dettagli
  78. Cazzola, M., Ora, J., & Puxeddu, E. (2016). Dual bronchodilation and exacerbations of COPD. JOURNAL OF THORACIC DISEASE, 8(9), 2383-2386 [10.21037/jtd.2016.08.92]. Dettagli
  79. Calzetta, L., Orlandi, A., Page, C., Rogliani, P., Rinaldi, B., Rosano, G., et al. (2016). Brain natriuretic peptide: Much more than a biomarker. INTERNATIONAL JOURNAL OF CARDIOLOGY, 221, 1031-1038 [10.1016/j.ijcard.2016.07.109]. Dettagli
  80. Calzetta, L., Ciaprini, C., Puxeddu, E., & Cazzola, M. (2016). Olodaterol + tiotropium bromide for the treatment of COPD. EXPERT REVIEW OF RESPIRATORY MEDICINE, 10(4), 379-386 [10.1586/17476348.2016.1156538]. Dettagli
  81. Blasi, F., Page, C., Rossolini, G.m., Pallecchi, L., Matera, M.g., Rogliani, P., et al. (2016). The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. RESPIRATORY MEDICINE, 117, 190-197 [10.1016/j.rmed.2016.06.015]. Dettagli
  82. Calzetta, L., Rogliani, P., Matera, M., & Cazzola, M. (2016). A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. CHEST, 149(5), 1181-1196. Dettagli
  83. Cazzola, M., & Rogliani, P. (2016). Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome?. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY [10.1016/j.jaci.2016.04.028]. Dettagli
  84. Cazzola, M., & Rogliani, P. (2016). LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. EVIDENCE-BASED MEDICINE, ebmed-2016-110525 [10.1136/ebmed-2016-110525]. Dettagli
  85. Cazzola, M., Calzetta, L., Puxeddu, E., Ora, J., Facciolo, F., Rogliani, P., et al. (2016). Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. RESPIRATORY RESEARCH, 17(1). Dettagli
  86. Cazzola, M., Calzetta, L., Rogliani, P., & Matera, M.g. (2016). The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON DRUG DISCOVERY, 11(7), 733-744 [10.1080/17460441.2016.1184642]. Dettagli
  87. Cazzola, M., Calzetta, L., Rogliani, P., Puxeddu, E., Facciolo, F., & Matera, M. (2016). Interaction between corticosteroids and muscarinic antagonists in human airways. PULMONARY PHARMACOLOGY & THERAPEUTICS, 36, 1-9 [10.1016/j.pupt.2015.11.004]. Dettagli
  88. Cazzola, M., Ora, J., Di Paolo, A., Puxeddu, E., Calzetta, L., & Rogliani, P. (2016). Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 39, 48-53 [10.1016/j.pupt.2016.06.006]. Dettagli
  89. Cazzola, M., Rogliani, P., Ora, J., & Matera, M.g. (2016). Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 17(7), 977-988 [10.1517/14656566.2016.1155555]. Dettagli
  90. D'Antonio, S., Rogliani, P., Paone, G., Altieri, A., Alma, M.g., Cazzola, M., et al. (2016). An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 5(2), 244-247 [10.1016/j.ijmyco.2016.04.001]. Dettagli
  91. Liccardi, G., Salzillo, A., Calzetta, L., Cazzola, M., Matera, M.g., & Rogliani, P. (2016). Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. RESPIRATORY MEDICINE, 117, 150-153 [10.1016/j.rmed.2016.05.026]. Dettagli
  92. Liccardi, G., Salzillo, A., Calzetta, L., Ora, J., Cazzola, M., Matera, M.g., et al. (2016). Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE, 4(4), 791-793 [10.1016/j.jaip.2016.03.025]. Dettagli
  93. Matera, M.g., Page, C., Rogliani, P., Calzetta, L., & Cazzola, M. (2016). Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. DRUGS, 76(13), 1257-1270 [10.1007/s40265-016-0625-9]. Dettagli
  94. Matera, M.g., Rogliani, P., Calzetta, L., & Cazzola, M. (2016). Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. DRUG SAFETY, 39(6), 501-508 [10.1007/s40264-016-0402-4]. Dettagli
  95. ROGLIANI, P., Calzetta, L., Cavalli, F., Matera, M., & CAZZOLA, M. (2016). Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 40, 95-103 [10.1016/j.pupt.2016.07.009]. Dettagli
  96. Rogliani, P., Calzetta, L., Capuani, B., Facciolo, F., Cazzola, M., Lauro, D., et al. (2016). Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 55(6), 804-814 [10.1165/rcmb.2015-0311OC]. Dettagli
  97. Rogliani, P., Calzetta, L., Cazzola, M., & Matera, M.g. (2016). Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. EXPERT OPINION ON DRUG SAFETY, 15(8), 1133-1146 [10.1080/14740338.2016.1199683]. Dettagli
  98. Rogliani, P., Ora, J., Puxeddu, E., & Cazzola, M. (2016). Airflow obstruction: Is it asthma or is it COPD?. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 11(1), 3007-3013 [10.2147/COPD.S54927]. Dettagli
  99. Rogliani, P., Puxeddu, E., Ciaprini, C., Ora, J., Onorato, A., Pezzuto, G., et al. (2016). The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. BIOMED RESEARCH INTERNATIONAL, 2016 [10.1155/2016/4547953]. Dettagli
  100. Cazzola, M., Rogliani, P., & Matera, M. (2015). Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. DRUGS, 75(14), 1575-1585 [10.1007/s40265-015-0450-6]. Dettagli
  101. Cazzola, M., Coppola, A., Rogliani, P., & Matera, M. (2015). Novel glucocorticoid receptor agonists in the treatment of asthma. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 24(11), 1473-1482 [10.1517/13543784.2015.1078310]. Dettagli
  102. Calzetta, L., Cazzola, M., Page, C.p., Rogliani, P., Facciolo, F., & Matera, M.g. (2015). Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. PULMONARY PHARMACOLOGY & THERAPEUTICS, 32, 15-23 [10.1016/j.pupt.2015.03.007]. Dettagli
  103. Calzetta, L., Luongo, L., Cazzola, M., Page, C., Rogliani, P., Facciolo, F., et al. (2015). Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. LIFE SCIENCES, 131, 44-50 [10.1016/j.lfs.2015.03.023]. Dettagli
  104. Cazzola, M., Calzetta, L., Matera, M.G., Muscoli, S., Rogliani, P., & Romeo, F. (2015). Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. RESPIRATORY MEDICINE, 109(8), 1019-1025 [10.1016/j.rmed.2015.05.021]. Dettagli
  105. Cazzola, M., Calzetta, L., Page, C., Jardim, J., Chuchalin, A., Rogliani, P., et al. (2015). Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. EUROPEAN RESPIRATORY REVIEW, 24(137), 451-461 [10.1183/16000617.00002215]. Dettagli
  106. Cazzola, M., Calzetta, L., Segreti, A., Facciolo, F., Rogliani, P., & Matera, M. (2015). Translational study searching for synergy between glycopyrronium and indacaterol. COPD, 12(2), 175-181 [10.3109/15412555.2014.922172]. Dettagli
  107. Cazzola, M., Rogliani, P., & Matera, M. (2015). Cardiovascular disease in patients with COPD. THE LANCET RESPIRATORY MEDICINE, 3(8), 593-595 [10.1016/S2213-2600(15)00279-9]. Dettagli
  108. Cazzola, M., Rogliani, P., Ora, J., & Matera, M.g. (2015). Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 8(5), 529-539 [10.1586/17512433.2015.1075389]. Dettagli
  109. Cazzola, M., Rogliani, P., Sanduzzi, A., & Matera, M.G. (2015). Influence of ethnicity on response to asthma drugs. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 11(7), 1089-1097 [10.1517/17425255.2015.1047341]. Dettagli
  110. Matera, M., Rogliani, P., & Cazzola, M. (2015). Indacaterol for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 16(1), 107-115 [10.1517/14656566.2015.983076]. Dettagli
  111. Matera, M.g., Cardaci, V., Cazzola, M., & Rogliani, P. (2015). Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. EXPERT OPINION ON DRUG SAFETY, 14(4), 533-541 [10.1517/14740338.2015.1001363]. Dettagli
  112. Matera, M.g., Rogliani, P., & Cazzola, M. (2015). QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 16(7), 1079-1090 [10.1517/14656566.2015.1032247]. Dettagli
  113. Rogliani, P., Calzetta, L., Ora, J., Lipsi, R., Segreti, A., Matera, M.g., et al. (2015). Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. EUROPEAN JOURNAL OF PHARMACOLOGY, 761, 383-390 [10.1016/j.ejphar.2015.04.042]. Dettagli
  114. Rogliani, P., Matera, M.g., & Cazzola, M. (2015). Fluticasone furoate/vilanterol combination for the treatment of asthma and COPD. DRUGS OF TODAY, 51(8), 469-478 [10.1358/dot.2015.51.8.2365401]. Dettagli
  115. Segreti, A., Calzetta, L., Rogliani, P., & Cazzola, M. (2014). Umeclidinium for the treatment of chronic obstructive pulmonary disease. EXPERT REVIEW OF RESPIRATORY MEDICINE, 8(6), 665-671. Dettagli
  116. Matera, M., Rogliani, P., Rinaldi, B., & Cazzola, M. (2014). Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 1-7. Dettagli
  117. Cazzola, M., Calzetta, L., Page, C., Rogliani, P., Facciolo, F., Gavaldà, A., et al. (2014). Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. EUROPEAN JOURNAL OF PHARMACOLOGY, 745C, 135-143. Dettagli
  118. Novelli, F., Latorre, M., Vergura, L., Caiaffa, M., Camiciottoli, G., Guarnieri, G., et al. (2014). Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. PULMONARY PHARMACOLOGY & THERAPEUTICS [10.1016/j.pupt.2014.09.007]. Dettagli
  119. Matera, M., Page, C., & Cazzola, M. (2014). PDE inhibitors currently in early clinical trials for the treatment of asthma. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 23(9), 1267-1275. Dettagli
  120. Bousquet, J., Addis, A., Adcock, I., Agache, I., Agusti, A., Alonso, A., et al. (2014). Integrated care pathways for airway diseases (AIRWAYS-ICPs). EUROPEAN RESPIRATORY JOURNAL, 44(2), 304-323. Dettagli
  121. Page, C., & Cazzola, M. (2014). Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. EUROPEAN RESPIRATORY JOURNAL, 44(2), 475-482. Dettagli
  122. Papi, A., Blasi, F., Canonica, G., Cazzola, M., Centanni, S., Foschino Barbaro, M., et al. (2014). Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage. EUROPEAN JOURNAL OF INTERNAL MEDICINE. Dettagli
  123. Cazzola, M., & Segreti, A. (2014). Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit. DRUGS, 74(5), 535-537. Dettagli
  124. Matera, M., Calzetta, L., Rogliani, P., Cesario, A., & Cazzola, M. (2014). New Treatments for COPD in the Elderly. CURRENT PHARMACEUTICAL DESIGN. Dettagli
  125. Calzetta, L., Passeri, D., Kanabar, V., Rogliani, P., Page, C., Cazzola, M., et al. (2014). Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 50(3), 493-501 [10.1165/rcmb.2013-0119OC]. Dettagli
  126. Cazzola, M., & Matera, M. (2014). Bronchodilators: current and future. CLINICS IN CHEST MEDICINE, 35(1), 191-201. Dettagli
  127. Cazzola, M., & Matera, M. (2014). N-acetylcysteine in COPD may be beneficial, but for whom?. THE LANCET RESPIRATORY MEDICINE, 2(3), 166-167. Dettagli
  128. Cazzola, M., Calzetta, L., Page, C., & Matera, M. (2014). Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 10(1), 129-137. Dettagli
  129. Calzetta, L., Rogliani, P., Cazzola, M., & Matera, M. (2014). Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. EXPERT OPINION ON DRUG DISCOVERY, 9(6), 595-607 [10.1517/17460441.2014.909403]. Dettagli
  130. Cazzola, M., & Matera, M. (2014). Triple combinations in chronic obstructive pulmonary disease – is three better than two?. EXPERT OPINION ON PHARMACOTHERAPY, 15(17), 2475-2478. Dettagli
  131. Cesario, A., Auffray, C., Agusti, A., Apolone, G., Balling, R., Barbanti, P., et al. (2014). A systems medicine clinical platform for understanding and managing non- communicable diseases. CURRENT PHARMACEUTICAL DESIGN, 20(38), 5945-5956. Dettagli
  132. Lipsi, R., Rogliani, P., Calzetta, L., Segreti, A., & Cazzola, M. (2014). The clinical use of regenerative therapy in COPD. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 9, 1389-1396 [10.2147/COPD.S49519]. Dettagli
  133. Matera, M., Rogliani, P., & Cazzola, M. (2014). Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 15(7), 961-977 [10.1517/14656566.2014.899581]. Dettagli
  134. Matera, M., Rogliani, P., Calzetta, L., & Cazzola, M. (2014). Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?. DRUGS, 74(17), 1983-1992 [10.1007/s40265-014-0303-8]. Dettagli
  135. Rogliani, P., Calzetta, L., Segreti, A., Barrile, A., & Cazzola, M. (2014). Diabetes mellitus among outpatients with COPD attending a university hospital. ACTA DIABETOLOGICA. Dettagli
  136. Rogliani, P., Ora, J., Ciaprini, C., Senis, L., Stirpe, E., & Cazzola, M. (2014). Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. RESPIRATORY MEDICINE, 108(2), 307-313 [10.1016/j.rmed.2013.10.022]. Dettagli
  137. Segreti, A., Stirpe, E., Rogliani, P., & Cazzola, M. (2014). Defining Phenotypes in COPD: An Aid to Personalized Healthcare. MOLECULAR DIAGNOSIS & THERAPY, 18(4), 381-388 [10.1007/s40291-014-0100-9]. Dettagli
  138. Franciosi, L., Diamant, Z., Banner, K., Zuiker, R., Morelli, N., Kamerling, I., et al. (2013). Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. THE LANCET RESPIRATORY MEDICINE, 1(9), 714-727. Dettagli
  139. Braido, F., Baiardini, I., Cazzola, M., Brusselle, G., Marugo, F., & Canonica, G. (2013). Long-acting bronchodilators improve health related quality of life in patients with COPD. RESPIRATORY MEDICINE, 107(10), 1465-1480. Dettagli
  140. Cazzola, M., Lopez-Campos, J., & Puente-Maestu, L. (2013). The MABA approach: a new option to improve bronchodilator therapy. EUROPEAN RESPIRATORY JOURNAL, 42(4), 885-887. Dettagli
  141. Matera, M., Calzetta, L., & Cazzola, M. (2013). β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. DRUGS, 73(15), 1653-1663. Dettagli
  142. Cazzola, M., Bardaro, F., & Stirpe, E. (2013). The role of indacaterol for chronic obstructive pulmonary disease (COPD). JOURNAL OF THORACIC DISEASE, 5(4), 559-566. Dettagli
  143. Alessandrino, E.P., Porta, M., Malcovati, L., Jackson, C.H., Pascutto, C., Bacigalupo, A., et al. (2013). Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. AMERICAN JOURNAL OF HEMATOLOGY, 88(7), 581-588 [10.1002/ajh.23458]. Dettagli
  144. Cazzola, M., Page, C., & Matera, M. (2013). Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. PULMONARY PHARMACOLOGY & THERAPEUTICS [10.1016/j.pupt.2012.12.006]. Dettagli
  145. Cazzola, M., Page, C.P., & Matera, M. (2013). Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY [10.1517/14656566.2013.789021]. Dettagli
  146. Cazzola, M., Brusasco, V., Centanni, S., Cerveri, I., De Michele, F., Di Maria, G., et al. (2013). Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. PULMONARY PHARMACOLOGY & THERAPEUTICS, 26(2), 218-228. Dettagli
  147. Cazzola, M., Rogliani, P., & Matera, M. (2013). Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 14(6), 775-781 [10.1517/14656566.2013.776539]. Dettagli
  148. Cazzola, M., Segreti, A., Stirpe, E., Puxeddu, E., Ora, J., Rogliani, P., et al. (2013). Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. RESPIRATORY MEDICINE, 107(1), 107-111 [10.1016/j.rmed.2012.09.022]. Dettagli
  149. Calzetta, L., Page, C., Spina, D., Cazzola, M., Rogliani, P., Facciolo, F., et al. (2013). Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 346(3), 414-423 [10.1124/jpet.113.204644]. Dettagli
  150. Cazzola, M., Calzetta, L., Lauro, D., Bettoncelli, G., Cricelli, C., DI DANIELE, N., et al. (2013). Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit. RESPIRATORY MEDICINE, 107(9), 1417-1422 [10.1016/j.rmed.2013.04.021]. Dettagli
  151. Cazzola, M., Page, C., Rogliani, P., & Matera, M. (2013). β2-Agonist Therapy in Lung Disease. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 187(7), 690-696 [10.1164/rccm.201209-1739PP]. Dettagli
  152. Cazzola, M., Rogliani, P., Novelli, L., & Matera, M. (2013). Inhaled corticosteroids for chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 14(18), 2489-2499 [10.1517/14656566.2013.848856]. Dettagli
  153. Cazzola, M., Rogliani, P., Ruggeri, P., Segreti, A., Proietto, A., Picciolo, S., et al. (2013). Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. RESPIRATORY MEDICINE, 107(6), 848-853 [10.1016/j.rmed.2013.02.008]. Dettagli
  154. Cazzola, M., Segreti, A., & Matera, M. (2013). New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. DRUG DESIGN, DEVELOPMENT AND THERAPY, 7, 1201-1208. Dettagli
  155. Cazzola, M., Segreti, A., Calzetta, L., & Rogliani, P. (2013). Comorbidities of asthma. CURRENT OPINION IN PULMONARY MEDICINE, 19(1), 36-41 [10.1097/MCP.0b013e32835b113a]. Dettagli
  156. Segreti, A., Fiori, E., Calzetta, L., Sabatini, M., Segreti, V., Rogliani, P., et al. (2013). The effect of indacaterol during an acute exacerbation of COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 26(6), 630-634. Dettagli
  157. Cazzola, M., Segreti, A., & Rogliani, P. (2012). Comparative effectiveness of drugs for chronic obstructive pulmonary disease. DRUGS OF TODAY, 48(12), 785-794 [10.1358/dot.2012.48.12.1860770]. Dettagli
  158. Cazzola, M., Calzetta, L., Rogliani, P., Lauro, D., Novelli, L., Page, C., et al. (2012). High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 47(4), 509-516 [10.1165/rcmb.2011-0449OC]. Dettagli
  159. Cazzola, M., Rogliani, P., Segreti, A., & Matera, M.G. (2012). An update on bronchodilators in Phase I and II clinical trials. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 21(10), 1489-1501. Dettagli
  160. Cazzola, M., Page, C.P., Calzetta, L., & Matera, M.G. (2012). Emerging anti-inflammatory strategies for COPD. EUROPEAN RESPIRATORY JOURNAL, 40(3), 724-741 [10.1183/09031936.00213711]. Dettagli
  161. Cazzola, M., Capuano, A., Rogliani, P., & Matera, M.C. (2012). Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. CURRENT OPINION IN PHARMACOLOGY, 12(3), 300-308 [10.1016/j.coph.2012.01.019]. Dettagli
  162. Cazzola, M., Page, C.P., Calzetta, L., & Matera, M.G. (2012). Pharmacology and therapeutics of bronchodilators. PHARMACOLOGICAL REVIEWS, 64(3), 450-504 [10.1124/pr.111.004580]. Dettagli
  163. Matera, M.G., & Cazzola, M. (2012). Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies. CURRENT OPINION IN PHARMACOLOGY [10.1016/j.coph.2012.03.006]. Dettagli
  164. Matera, M.G., Calzetta, L., Rinaldi, B., & Cazzola, M. (2012). Treatment of COPD: moving beyond the lungs. CURRENT OPINION IN PHARMACOLOGY [10.1016/j.coph.2012.04.001]. Dettagli
  165. Cazzola, M., & Matera, M.G. (2012). Lung blood flow must be considered when prescribing a long-acting β2-agonist/inhaled corticosteroid combination. CHEST, 141(5), 1134-1136 [10.1378/chest.11-2497]. Dettagli
  166. Cazzola, M., & Matera, M.G. (2012). IL-17 in chronic obstructive pulmonary disease. EXPERT REVIEW OF RESPIRATORY MEDICINE, 6(2), 135-138 [10.1586/ers.12.7]. Dettagli
  167. Cazzola, M., Paggiaro, P., Palange, P., Bjermer, L., Ausin, P., Carlsson, L.G., et al. (2012). Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study. CLINICAL DRUG INVESTIGATION [10.2165/11630880-000000000-00000]. Dettagli
  168. Matera, M.G., Calzetta, L., Segreti, A., & Cazzola, M. (2012). Emerging drugs for chronic obstructive pulmonary disease. EXPERT OPINION ON EMERGING DRUGS, 17(1), 61-82 [10.1517/14728214.2012.660917]. Dettagli
  169. van der Molen, T., & Cazzola, M. (2012). Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. PRIMARY CARE RESPIRATORY JOURNAL. Dettagli
  170. Cazzola, M., & Matera, M.G. (2012). Tremor and β2-adrenergic agents: is it a real clinical problem?. PULMONARY PHARMACOLOGY & THERAPEUTICS, 25(1), 4-10 [10.1016/j.pupt.2011.12.004]. Dettagli
  171. Cazzola, M., Calzetta, L., Bettoncelli, G., Cricelli, C., Romeo, F., Matera, M., et al. (2012). Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. RESPIRATORY MEDICINE, 106(2), 249-256 [10.1016/j.rmed.2011.07.021]. Dettagli
  172. Rossi, A., Centanni, S., Cerveri, I., Gulotta, C., Foresi, A., Cazzola, M., et al. (2012). Acute effects of indacaterol on lung hyperinflation in moderate COPD: A comparison with tiotropium. RESPIRATORY MEDICINE, 106(1), 84-90 [10.1016/j.rmed.2011.09.006]. Dettagli
  173. Hewson, C., Patel, S., Calzetta, L., Campwala, H., Havard, S., Luscombe, E., et al. (2011). Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthma. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. Dettagli
  174. Calzetta, L., Spina, D., Cazzola, M., Page, C., Facciolo, F., Rendina, E., et al. (2011). Pharmacological characterization of adenosine receptors on isolated human bronchi. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 45(6), 1222-1231. Dettagli
  175. Cazzola, M., Anapurapu, S., & Page, C. (2011). Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS. Dettagli
  176. Cazzola, M., & Matera, M. (2011). Inhibiting or blocking LIGHT, a TNF superfamily member, for treating airway remodeling. EXPERT REVIEW OF RESPIRATORY MEDICINE, 5(5), 623-625. Dettagli
  177. Cazzola, M., Calzetta, L., Page, C., Rinaldi, B., Capuano, A., & Matera, M. (2011). Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 45(4), 704-710. Dettagli
  178. Cazzola, M., Segreti, A., Bettoncelli, G., Calzetta, L., Cricelli, C., Pasqua, F., et al. (2011). Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. PRIMARY CARE RESPIRATORY JOURNAL, 20(3), 291-298. Dettagli
  179. Agusti, A., Hedner, J., Marin, J., Barbé, F., Cazzola, M., & Rennard, S. (2011). Night-time symptoms: a forgotten dimension of COPD. European respiratory review : an official journal of the European Respiratory Society, 20(121), 183-194. Dettagli
  180. Cazzola, M., Segreti, A., Bettoncelli, G., Calzetta, L., Cricelli, C., Pasqua, F., et al. (2011). Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. PRIMARY CARE RESPIRATORY JOURNAL, 20(3), 291-298. Dettagli
  181. Cazzola, M., Calzetta, L., Bettoncelli, G., Cricelli, C., Romeo, F., Matera, M.G., et al. (2011). Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. RESPIRATORY MEDICINE. Dettagli
  182. Matera, M., Calzetta, L., Passeri, D., Facciolo, F., Rendina, E., Page, C., et al. (2011). Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. BRITISH JOURNAL OF PHARMACOLOGY, 163(8), 1740-1754 [10.1111/j.1476-5381.2011.01339.x]. Dettagli
  183. Matera, M., Page, C., & Cazzola, M. (2011). Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. TRENDS IN PHARMACOLOGICAL SCIENCES, 32(8), 495-506. Dettagli
  184. Cazzola, M., Calzetta, L., Bettoncelli, G., Novelli, L., Cricelli, C., & Rogliani, P. (2011). Asthma and comorbid medical illness. EUROPEAN RESPIRATORY JOURNAL, 38(1), 42-49 [10.1183/09031936.00140310]. Dettagli
  185. Cazzola, M., Calzetta, L., Bettoncelli, G., Novelli, L., Cricelli, C., & Rogliani, P. (2011). Asthma and comorbid medical illness. EUROPEAN RESPIRATORY JOURNAL, 38(1), 42-49 [10.1183/09031936.00140310]. Dettagli
  186. Cazzola, M., Calzetta, L., & Matera, M. (2011). β(2) -adrenoceptor agonists: current and future direction. BRITISH JOURNAL OF PHARMACOLOGY, 163(1), 4-17. Dettagli
  187. Matera, M., Calzetta, L., Rogliani, P., Bardaro, F., Page, C., & Cazzola, M. (2011). Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. PULMONARY PHARMACOLOGY & THERAPEUTICS, 24(2), 221-226. Dettagli
  188. Cazzola, M., Puxeddu, E., Bettoncelli, G., Novelli, L., Segreti, A., Cricelli, C., et al. (2011). The prevalence of asthma and COPD in Italy: a practice-based study. RESPIRATORY MEDICINE, 105(3), 386-391 [10.1016/j.rmed.2010.09.022]. Dettagli
  189. Kessler, R., Partridge, M., Miravitlles, M., Cazzola, M., Vogelmeier, C., Leynaud, D., et al. (2011). Symptom variability in patients with severe COPD: a pan-European cross-sectional study. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology, 37(2), 264-272. Dettagli
  190. Cazzola, M., & Novelli, G. (2010). Biomarkers in COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(6), 493-500 [10.1016/j.pupt.2010.05.001]. Dettagli
  191. Rogliani, P., Curradi, G., Mura, M., Lauro, D., Federici, M., Galli, A., et al. (2010). Metabolic syndrome and risk of pulmonary involvement. RESPIRATORY MEDICINE, 104(1), 47-51 [10.1016/j.rmed.2009.08.009]. Dettagli
  192. Capuano, R., Santonico, M., Martinelli, E., Pennazza, G., Paolesse, R., Bergamini, A., et al. (2010). COPD diagnosis by a gas sensor array. In Procedia engineering (pp.484-487). Elsevier. Dettagli
  193. Cazzola, M. (2010). The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 4(4), 195-198. Dettagli
  194. Cazzola, M., & Molimard, M. (2010). The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(4), 257-267. Dettagli
  195. Cazzola, M., Bettoncelli, G., Sessa, E., Cricelli, & C, B. (2010). Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. RESPIRATION, 80(2), 112-119. Dettagli
  196. Cazzola, M., Calzetta, L., & Matera, M.G. (2010). The cardiovascular risk of tiotropium: is it real?. EXPERT OPINION ON DRUG SAFETY, 9(5), 783-792. Dettagli
  197. Cazzola, M., Camiciottoli, G., Bonavia, M., Gulotta, C., Ravazzi, A., Alessandrini, A., et al. (2010). Italian real-life experience of omalizumab. RESPIRATORY MEDICINE, 104(10), 1410-1416. Dettagli
  198. Cazzola, M., Floriani, I., & Page, C.P. (2010). The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(2), 135-144. Dettagli
  199. Cazzola, M., Hanania, N.A., & Matera, M.G. (2010). Arformoterol tartrate in the treatment of COPD. EXPERT REVIEW OF RESPIRATORY MEDICINE, 4(2), 155-162. Dettagli
  200. Cazzola, M., Pasqua, F., Ferri, L., Biscione, G., Cardaci, V., & Matera, M.G. (2010). Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 24(1), 118-122. Dettagli
  201. Cazzola, M., Pham-Thi, N., Kerihuel, J.C., Durand, H., & Bohbot, S. (2010). Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study. Therapeutic Advances in Respiratory Diseases, 4(5), 271-278. Dettagli
  202. Cazzola, M., Picciolo, S., & Matera, M.G. (2010). Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. EXPERT OPINION ON PHARMACOTHERAPY, 11(3), 441-449. Dettagli
  203. Cazzola, M., Proietto, A., & Matera, M.G. (2010). Indacaterol for chronic obstructive pulmonary disease (COPD). DRUGS OF TODAY, 46(3), 139-150. Dettagli
  204. Cazzola, M., Segreti, A., & Matera, M.G. (2010). Novel bronchodilators in asthma. CURRENT OPINION IN PULMONARY MEDICINE, 16(1), 6-12. Dettagli
  205. Cazzola, M., Segreti, A., Stirpe, E., Appodia, M., Senis, L., & Matera, M.G. (2010). Energy expenditure and impact of bronchodilators in COPD patients. RESPIRATORY MEDICINE CME, 104(10), 1490-1494. Dettagli
  206. Cazzola, M., Tompkins, T.A., & Matera, M.G. (2010). Immunomodulatory impact of a synbiotic in T(h)1 and T(h)2 models of infection. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 4(5), 259-270. Dettagli
  207. Di Marco, F., Guazzi, M., Vicenzi, M., Santus, P., Cazzola, M., Pappalettera, M., et al. (2010). Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(3), 159-164. Dettagli
  208. Gallelli, L., Pelaia, G., Fratto, D., Muto, V., Falcone, D., Vatrella, A., et al. (2010). Effects of budesonide on P38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 23(2), 471-479. Dettagli
  209. Matera, M.G., Calzetta, L., & Cazzola, M. (2010). TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(2), 121-128. Dettagli
  210. Matera, M.G., Martuscelli, E., & Cazzola, M. (2010). Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(1), 1-8. Dettagli
  211. Pasqua, F., Biscione, G., Crigna, G., Auciello, L., & Cazzola, M. (2010). Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. RESPIRATORY MEDICINE, 104(3), 412-417. Dettagli
  212. Tannu, S.A., Renzetti, L.M., Tare, N., Ventre, J.D., Lavelle, D., Lin, T.A., et al. (2010). Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors. BRITISH JOURNAL OF PHARMACOLOGY, 161(6), 1329-1342. Dettagli
  213. Cazzola, M., & Tashkin, D. (2009). Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD, 6(5), 404-415. Dettagli
  214. Cazzola M. (2009). Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 10(5), 482-490. Dettagli
  215. Cazzola M., B.G. (2009). Primary care of the patient with chronic obstructive pulmonary disease in Italy. RESPIRATORY MEDICINE, 103(4), 582-588. Dettagli
  216. Cazzola, M. (2009). Diagnostic approach: clinical implications of the new experimental evidence. In MULTIDISCIPLINARY RESPIRATORY MEDICINE (pp.55-56). BORGOMANERO : NOVAMEDIA. Dettagli
  217. Cazzola, M. (2009). Pharmacology of the small airways [Farmacologia delle piccole vie aeree]. RASSEGNA DI PATOLOGIA DELL’APPARATO RESPIRATORIO, 24(1, S. 1), 19-26. Dettagli
  218. Cazzola, M., Mura, M., Segreti, A., Mattei, M.A., & Rogliani, P. (2009). Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: Forme-fruste of Churg-Strauss syndrome?. ALLERGY, 64(9), 1389-1390. Dettagli
  219. Cazzola, M., Noschese, P., & Di Perna, F. (2009). Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 3(2), 59-63 [10.1177/1753465809104677]. Dettagli
  220. Cazzola, M., Rogliani, P., Curradi, G., Segreti, A., Ciaprini, C., Pezzuto, G., et al. (2009). A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 22(6), 522-525 [10.1016/j.pupt.2009.05.005]. Dettagli
  221. Cazzola, M., Santus, P., D'Adda, A., Pizzolato, S., Di Marco, F., & Centanni, S. (2009). Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 22(3), 177-182 [10.1016/j.pupt.2008.10.010]. Dettagli
  222. Comandini, A., Rogliani, P., Nunziata, A., Cazzola, M., Curradi, G., & Saltini, C. (2009). Biomarkers of lung damage associated with tobacco smoke in induced sputum. RESPIRATORY MEDICINE, 103(11), 1592-1613 [10.1016/j.rmed.2009.06.002]. Dettagli
  223. Matera, M., Calzetta, L., Parascandolo, V., Curradi, G., Rogliani, P., & Cazzola, M. (2009). Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. PULMONARY PHARMACOLOGY & THERAPEUTICS, 22(6), 478-482. Dettagli
  224. Ando F., R.P. (2008). Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD. RESPIRATORY MEDICINE, 102(6), 815-818. Dettagli
  225. Braido F., B.M. (2008). The role of Pneumococcal vaccine. PULMONARY PHARMACOLOGY & THERAPEUTICS, 21(4), 608-615. Dettagli
  226. Brozek J., A.E. (2008). Long-acting beta2-agonists for chronic obstructive pulmonary disease: Serious adverse events. COCHRANE DATABASE OF SYSTEMATIC REVIEWS(3). Dettagli
  227. Cazzola M., B.G. (2008). Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD. RESPIRATORY MEDICINE, 102(10), 1425-1430. Dettagli
  228. Cazzola, M. (2008). Physiologic and biological markers to assess the progression of chronic obstructive pulmonary disease [Quali parametri funzionali e biologici per la valutazione della progressione della broncopneumopatia cronica ostruttiva]. RASSEGNA DI PATOLOGIA DELL’APPARATO RESPIRATORIO, 23(1), 26-34. Dettagli
  229. Cazzola, M., & Matera, M.G. (2008). Novel long-acting bronchodilators for COPD and asthma. BRITISH JOURNAL OF PHARMACOLOGY, 155(3), 291-299. Dettagli
  230. Cazzola, M., & Matera, M.G. (2008). Treatment of asthma during pregnancy: more solid evidence needed. THORAX, 63(11), 944-945. Dettagli
  231. Cazzola, M., & Matera, M.G. (2008). ß-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 178(7), 661-662 [10.1164/rccm.200806-963ED]. Dettagli
  232. Cazzola, M., Brusasco, V., & Martinez, F.J. (2008). From the authors. EUROPEAN RESPIRATORY JOURNAL, 32(2), 528. Dettagli
  233. Cazzola, M., Donner, C., & Hanania, N.A. (2008). One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD). Republished article. RESPIRATORY MEDICINE, 4(1), 8-25 [10.1016/j.rmedu.2007.11.019]. Dettagli
  234. Cazzola, M., Hanania, N.A., Jones, P.W., Mahler, D.A., Make, B., Ohar, J., et al. (2008). It's about time: directing our attention toward modifying the course of COPD. In Respiratory medicine (pp.37-48). London : Saunders [10.1016/S0954-6111(08)70006-4]. Dettagli
  235. Cazzola, M., MacNee, W., Martinez, F., Rabe, K., Franciosi, L., Barnes, P., et al. (2008). Outcomes for COPD pharmacological trials: From lung function to biomarkers. EUROPEAN RESPIRATORY JOURNAL, 31(2), 416-468. Dettagli
  236. Cazzola, M., Rogliani, P., & Curradi, G. (2008). Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view. RESPIRATORY MEDICINE, 102(3), 321-327 [10.1016/j.rmed.2007.11.002]. Dettagli
  237. Matera M.G., C.G. (2008). Long-acting ß2 agonists in asthma and allergic rhinitis. EXPERT OPINION ON PHARMACOTHERAPY, 9(9), 1531-1539. Dettagli
  238. Matera, M., Calzetta, L., Sanduzzi, A., Page, C., & Cazzola, M. (2008). Effects of neuraminidase on equine isolated bronchi. PULMONARY PHARMACOLOGY & THERAPEUTICS, 21(4), 624-629. Dettagli
  239. Pelaia, G., Renda, T., Gallelli, L., Vatrella, A., Busceti, M.T., Agati, S., et al. (2008). Molecular mechanisms underlying airway smooth muscle contraction and proliferation: implications for asthma. RESPIRATORY MEDICINE, 102(8), 1173-1181 [10.1016/j.rmed.2008.02.020]. Dettagli
  240. Cazzola M. (2007). Adequate surrogate parameters in COPD studies [Surrogatparameter bei COPD]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 132(10), 522-523. Dettagli
  241. Cazzola M. (2007). Editorial. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 1(1), 3-4. Dettagli
  242. Cazzola M., A.F. (2007). A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 20(5), 556-561 [10.1016/j.pupt.2006.06.001]. Dettagli
  243. Cazzola M., C.G. (2007). How to prevent relapse after acute exacerbation of asthma?. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 117, 487-490. Dettagli
  244. Cazzola M., M.M. (2007). Safety of long-acting ß2-agonists in the treatment of asthma. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 1(1), 35-46. Dettagli
  245. Cazzola, M., & Matera, M.G. (2007). The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study. RESPIRATORY MEDICINE, 101(5), 957-962. Dettagli
  246. Cazzola, M., Donner, C.F., & Hanania, N.A. (2007). One hundred years of chronic obstructive pulmonary disease (COPD). RESPIRATORY MEDICINE, 101(6), 1049-1065 [10.1016/j.rmed.2007.01.015]. Dettagli
  247. Cazzola, M., Matera, M.G., Rogliani, P., & Page, C. (2007). Treating systemic effects of COPD. TRENDS IN PHARMACOLOGICAL SCIENCES, 28(10), 544-550. Dettagli
  248. Matera, M.G., & Cazzola, M. (2007). Ultra-long-acting beta(2)-adrenoceptor agonists - An emerging therapeutic option for asthma and COPD?. DRUGS, 67(4), 503-515 [10.2165/00003495-200767040-00002]. Dettagli
  249. Raimondi G., C.S. (2007). Autonomic nervous system dysfunction in the course of active pulmonary tuberculosis. RESPIRATORY MEDICINE, 101(8), 1804-1808. Dettagli
  250. Santus, P., Centanni, S., Morelli, N., Di Marco, F., Verga, M., & Cazzola, M. (2007). Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta(2)-agonists. RESPIRATORY MEDICINE, 101(8), 1798-1803 [10.1016/j.rmed.2007.02.007]. Dettagli
  251. Vatrella, A., Bocchino, M., Perna, F., Scarpa, R., Galati, D., Spina, S., et al. (2007). Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement. RESPIRATORY MEDICINE, 101(7), 1383-1389 [10.1016/j.rmed.2007.02.003]. Dettagli
  252. Cazzola M., M.M. (2006). The effective treatment of COPD: Anticholinergics and what else?. DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, 3(3), 277-286. Dettagli
  253. Cazzola M., M.M. (2005). Inflammation - A new therapeutic target in pneumonia. RESPIRATION, 72(2), 117-126. Dettagli
  254. Cazzola M., S.C. (2005). Novel approaches to the treatment of bacterial lower respiratory tract infections: Introduction. RESPIRATION, 72(1), 7-8. Dettagli